Investigating The Effect Of IMT In Children And Adults With CF


Therapeutic category
Trial status
Completed Participating Centres
Not Applicable

Full title

Investigating the influence of an Inspiratory Muscle Training program on lung function and quality of life in children and adults with Cystic Fibrosis

The Cystic Fibrosis working group recent recommendations commended the use of physical exercise as part of a multidisciplinary therapeutic strategy, as it has been proven to lower mortality risks in patients. One nonpharmacological intervention which has shown some promising results in recent years is inspiratory muscle training (IMT), which may improve patients’ respiratory muscle and exercise function. Inspiratory muscle training, which involves breathing through a device that provides resistance when you breathe, aims to improve the strength of the lung muscles by making them work harder and therefore making them stronger. Starting IMT in children at the early years of their disease is essential in gaining early health benefits. With adults, Lands et al (1992) found that in later stages of Cystic Fibrosis it is difficult to maintain inspiratory muscle strength, therefore adults adopting IMT training at this stage could increase their muscle strength. In the past 30 years’ life expectancy in Cystic Fibrosis has increased significantly, however as age progresses lung function declines. Therefore, it is essential to determine IMT’s effectiveness in progression from childhood to adulthood. For this new generation of ageing patients, improving lung function and enhancing quality of life is a new challenge for a CF clinical care team, therefore, this potential non-pharmacological intervention warrants further investigation.
Trial Reference Number
Trial type
Length of participation
8 - 16 weeks
PrO2 Fit - inspiratory muscle training device
Recruitment target
Last edited date
CF sponsor
Swansea University
CF sponsor type

Who can take part?

Top inclusion criteria
  • Age 8 years or older who attend Paediatric Cystic Fibrosis Unit at Morriston Hospital and Southampton General Hospital
  • Age 18 years or older who attend adult Cystic Fibrosis Unit at University Hospital Llandough
  • Lung function considered stable and within 10% of their best in the preceding 6 months
Top exclusion criteria
  • Patients with severe lung deterioration
  • Patients with Bukholderia cepacian infection and nontuberculous mycobacteria
  • Patients with cor pulmonale, liver cirrhosis and or diabetes mellitus or any non-pulmonary condition that may impair exercise ability and cardiovascular disease

Your donation will make a difference:

Select amount